Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Malaria, Falciparum | 2 | 2014 | 10 | 0.270 |
Why?
|
| Parvoviridae Infections | 1 | 2003 | 2 | 0.220 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2003 | 13 | 0.220 |
Why?
|
| HIV | 1 | 2003 | 56 | 0.210 |
Why?
|
| Malaria Vaccines | 3 | 2014 | 4 | 0.210 |
Why?
|
| Hemoglobins | 1 | 2003 | 120 | 0.210 |
Why?
|
| Plasmodium falciparum | 3 | 2014 | 45 | 0.210 |
Why?
|
| Anopheles | 1 | 1997 | 3 | 0.150 |
Why?
|
| Insect Vectors | 1 | 1997 | 9 | 0.150 |
Why?
|
| Malaria | 4 | 2002 | 26 | 0.140 |
Why?
|
| HIV Infections | 1 | 2003 | 791 | 0.120 |
Why?
|
| Sporozoites | 1 | 2014 | 1 | 0.120 |
Why?
|
| Eye Infections, Bacterial | 1 | 1994 | 15 | 0.120 |
Why?
|
| Uveitis, Anterior | 1 | 1994 | 15 | 0.120 |
Why?
|
| Tetanus Toxoid | 3 | 1999 | 11 | 0.120 |
Why?
|
| Chloroquine | 3 | 1999 | 21 | 0.120 |
Why?
|
| Primaquine | 3 | 1999 | 12 | 0.120 |
Why?
|
| Syphilis | 1 | 1994 | 15 | 0.120 |
Why?
|
| Antimalarials | 3 | 1999 | 71 | 0.110 |
Why?
|
| Cryopreservation | 1 | 2014 | 103 | 0.110 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2010 | 2 | 0.090 |
Why?
|
| Mediastinal Diseases | 1 | 2010 | 15 | 0.090 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2010 | 16 | 0.090 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2010 | 61 | 0.090 |
Why?
|
| Strongyloides | 1 | 2008 | 2 | 0.080 |
Why?
|
| Antinematodal Agents | 1 | 2008 | 4 | 0.080 |
Why?
|
| Strongyloidiasis | 1 | 2008 | 5 | 0.080 |
Why?
|
| Ivermectin | 1 | 2008 | 12 | 0.080 |
Why?
|
| Diphtheria Toxoid | 2 | 1998 | 5 | 0.080 |
Why?
|
| Antigens, Protozoan | 2 | 1998 | 10 | 0.080 |
Why?
|
| Lymphocyte Activation | 2 | 1999 | 397 | 0.070 |
Why?
|
| Parasitemia | 2 | 2014 | 5 | 0.070 |
Why?
|
| Amphotericin B | 1 | 2005 | 26 | 0.070 |
Why?
|
| Fluconazole | 1 | 2005 | 26 | 0.070 |
Why?
|
| Candidiasis | 1 | 2005 | 39 | 0.060 |
Why?
|
| Triazoles | 1 | 2005 | 43 | 0.060 |
Why?
|
| Adult | 12 | 2014 | 21403 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2005 | 108 | 0.060 |
Why?
|
| Male | 14 | 2014 | 37321 | 0.060 |
Why?
|
| Persian Gulf Syndrome | 1 | 2004 | 27 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2005 | 178 | 0.060 |
Why?
|
| Mycoplasma Infections | 1 | 2004 | 40 | 0.060 |
Why?
|
| Doxycycline | 1 | 2004 | 49 | 0.060 |
Why?
|
| Parvovirus B19, Human | 1 | 2003 | 1 | 0.060 |
Why?
|
| Hematocrit | 1 | 2003 | 70 | 0.050 |
Why?
|
| Vaccines, Attenuated | 2 | 2002 | 10 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2003 | 205 | 0.050 |
Why?
|
| Anti-HIV Agents | 1 | 2003 | 135 | 0.050 |
Why?
|
| Humans | 15 | 2014 | 68618 | 0.050 |
Why?
|
| Mass Media | 1 | 2000 | 29 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2000 | 83 | 0.040 |
Why?
|
| Influenza, Human | 1 | 2000 | 79 | 0.040 |
Why?
|
| Tetanus Toxin | 1 | 1999 | 2 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 1999 | 38 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 1998 | 19 | 0.040 |
Why?
|
| Viral Vaccines | 1 | 1998 | 17 | 0.040 |
Why?
|
| Protozoan Proteins | 1 | 1998 | 25 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 1998 | 90 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 1998 | 63 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 1026 | 0.040 |
Why?
|
| Middle Aged | 5 | 2005 | 21147 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 1997 | 94 | 0.040 |
Why?
|
| Viral Proteins | 1 | 1998 | 150 | 0.040 |
Why?
|
| Platelet Count | 1 | 1997 | 100 | 0.040 |
Why?
|
| Veterans | 1 | 2004 | 904 | 0.030 |
Why?
|
| Insect Bites and Stings | 1 | 1997 | 47 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 649 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2014 | 1738 | 0.030 |
Why?
|
| Tonsillitis | 1 | 1995 | 2 | 0.030 |
Why?
|
| Animals | 5 | 2014 | 20881 | 0.030 |
Why?
|
| Adolescent | 4 | 2005 | 8912 | 0.030 |
Why?
|
| Penicillin G | 1 | 1994 | 8 | 0.030 |
Why?
|
| Injections, Intradermal | 1 | 2014 | 6 | 0.030 |
Why?
|
| alpha-Thalassemia | 1 | 2014 | 7 | 0.030 |
Why?
|
| Tanzania | 1 | 2014 | 35 | 0.030 |
Why?
|
| Immunocompromised Host | 2 | 2008 | 55 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 1995 | 163 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 1995 | 1851 | 0.030 |
Why?
|
| Genotype | 1 | 2014 | 786 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2010 | 123 | 0.020 |
Why?
|
| Ileum | 1 | 2008 | 28 | 0.020 |
Why?
|
| Female | 6 | 2005 | 38074 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2010 | 147 | 0.020 |
Why?
|
| Diphtheria-Tetanus Vaccine | 2 | 1998 | 5 | 0.020 |
Why?
|
| Vaccines, Combined | 2 | 1998 | 8 | 0.020 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 85 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 1999 | 1083 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 1999 | 1447 | 0.020 |
Why?
|
| Voriconazole | 1 | 2005 | 11 | 0.020 |
Why?
|
| APACHE | 1 | 2005 | 41 | 0.020 |
Why?
|
| Mycoplasma | 1 | 2004 | 10 | 0.020 |
Why?
|
| Photosensitivity Disorders | 1 | 2004 | 7 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 1997 | 7277 | 0.020 |
Why?
|
| T-Lymphocytes | 2 | 1999 | 597 | 0.010 |
Why?
|
| Nausea | 1 | 2004 | 47 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2004 | 150 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 5717 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2005 | 7029 | 0.010 |
Why?
|
| Culicidae | 1 | 2002 | 12 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2002 | 137 | 0.010 |
Why?
|
| Immunization | 1 | 2002 | 86 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2004 | 402 | 0.010 |
Why?
|
| Government Agencies | 1 | 2000 | 12 | 0.010 |
Why?
|
| Private Sector | 1 | 2000 | 19 | 0.010 |
Why?
|
| Michigan | 1 | 2000 | 68 | 0.010 |
Why?
|
| Drug Industry | 1 | 2000 | 54 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2000 | 285 | 0.010 |
Why?
|
| Placebos | 1 | 1999 | 195 | 0.010 |
Why?
|
| Antibodies, Protozoan | 1 | 1998 | 15 | 0.010 |
Why?
|
| Consumer Product Safety | 1 | 1998 | 32 | 0.010 |
Why?
|
| Apicomplexa | 1 | 1998 | 2 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1998 | 93 | 0.010 |
Why?
|
| Immunization, Secondary | 1 | 1997 | 17 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1998 | 79 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1998 | 312 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1997 | 114 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 1998 | 97 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1998 | 532 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 4848 | 0.010 |
Why?
|
| Vaccination | 1 | 1997 | 189 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1998 | 481 | 0.010 |
Why?
|
| Hypertrophy | 1 | 1995 | 89 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 1995 | 77 | 0.010 |
Why?
|
| Tonsillectomy | 1 | 1995 | 69 | 0.010 |
Why?
|
| Recurrence | 1 | 1995 | 948 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1995 | 1553 | 0.010 |
Why?
|
| Aged | 1 | 2005 | 14862 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1995 | 3187 | 0.000 |
Why?
|
| Mice | 1 | 1998 | 8474 | 0.000 |
Why?
|
| Child | 1 | 1995 | 6405 | 0.000 |
Why?
|